{"id":92328,"date":"2026-05-07T12:37:08","date_gmt":"2026-05-07T12:37:08","guid":{"rendered":"https:\/\/diyhaven858.wasmer.app\/index.php\/fda-to-reconsider-treatment-for-rare-cancer-after-its-surprise-rejection\/"},"modified":"2026-05-07T12:37:08","modified_gmt":"2026-05-07T12:37:08","slug":"fda-to-reconsider-treatment-for-rare-cancer-after-its-surprise-rejection","status":"publish","type":"post","link":"https:\/\/diyhaven858.wasmer.app\/index.php\/fda-to-reconsider-treatment-for-rare-cancer-after-its-surprise-rejection\/","title":{"rendered":"FDA to reconsider treatment for rare cancer after its surprise rejection"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div data-author=\"adam-feuerstein\">\n<p class=\"author-bio\">Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam\u2019s Biotech Scorecard. You can reach Adam on Signal at stataf.54.<\/p>\n<\/div>\n<div>\n<p>Two companies developing a therapy for a rare blood cancer have reached an agreement with the Food and Drug Administration that walked back the agency\u2019s main reason for rejecting the drug in January.\u00a0<\/p>\n<p>Pierre Fabre Pharmaceuticals and Atara Biotherapeutics, makers of the drug called Ebvallo, said Thursday that a meeting held in late April with FDA officials ended with the agency agreeing that their already completed, single-arm clinical trial was sufficient to support a review and potential approval.\u00a0<\/p>\n<p>When the FDA rejected Ebvallo, the agency said the same study was flawed and the data produced from it was \u201cinsufficient\u201d to support the drug\u2019s approval. The drug\u2019s review was conducted by the FDA\u2019s Center for Biologics Evaluation and Research, led at the time by Vinay Prasad. He departed the agency at the end of April.\u00a0<\/p>\n<div class=\"restricted-content-breaker article\" aria-labelledby=\"restricted-story-heading\" aria-describedby=\"restricted-story-description\" checked=\"false\">\n<div class=\"restricted-content-breaker-bar\">\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? Log in<\/p>\n<\/p><\/div>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<div class=\"restricted-content-breaker-wrapper\">\n\t\t\t\t<span class=\"stat-paywall-archive\"><\/p>\n<p>\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t<\/span><\/p>\n<h2 id=\"restricted-story-heading\">This article is exclusive to STAT+ subscribers<\/h2>\n<h3 id=\"restricted-story-description\">Unlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/h3>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? Log in<\/p>\n<div class=\"restricted-content-breaker-cards\">\n<div class=\"slider-container\" aria-label=\"Subscription plan toggle\">\n\t\t\t\t\t\t<button type=\"button\" class=\"individual\" aria-pressed=\"false\">Individual plans<\/button><\/p>\n<p>\t\t\t\t\t\t<button type=\"button\" class=\"group\" aria-pressed=\"false\">Group plans<\/button>\n\t\t\t\t\t<\/div>\n<\/p><\/div>\n<p>\t\t\t\tView All Plans\n\t\t\t<\/p><\/div>\n<\/p><\/div>\n<div class=\"restricted-message-breaker\">\n<div class=\"restricted-content-wrapper\">\n<div class=\"restricted-content-message\">\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\tSubscribe\n\t\t\t\t\t\t\t\t\t<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<p><br \/>\n<br \/><<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam\u2019s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Two companies developing a therapy [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":62175,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-92328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/03\/GettyImages-1227710555-1024x576.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/92328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=92328"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/92328\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/62175"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=92328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=92328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=92328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}